GBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-06-09), Generation Bio Co's Intrinsic Value: Projected FCF is $0.00. The stock price of Generation Bio Co is $3.26. Therefore, Generation Bio Co's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.
The historical rank and industry rank for Generation Bio Co's Intrinsic Value: Projected FCF or its related term are showing as below:
The historical data trend for Generation Bio Co's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generation Bio Co Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | - | - | - | - | - |
Generation Bio Co Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Generation Bio Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Generation Bio Co's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Generation Bio Co's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Generation Bio Co (NAS:GBIO) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Generation Bio Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 3.26 | / | ||
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Generation Bio Co's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Dannielle Appelhans | director | C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139 |
Rowland Charles A Jr | director | 3338 LANCASHIRE RD, FURLONG PA 18925 |
Donald William Nicholson | director | C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142 |
Anthony G. Quinn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPWY, STE. 250, AUSTIN TX 78746 |
Antoinette Paone | officer: CHIEF OPERATING OFFICER | C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142 |
Yalonda Howze | officer: CHIEF LEGAL OFFICER | C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140 |
Phillip Samayoa | officer: CHIEF STRATEGY OFFICER | C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142 |
Jason P Rhodes | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Associates X, L.p. | 10 percent owner | 400 TECHNOLOGY SQ., 10TH FLOOR, CAMBRIDGE MA 02139 |
Matthew Stanton | officer: Chief Scientific Officer | C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142 |
Douglas Kerr | officer: Chief Development Officer | C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142 |
Geoff Mcdonough | director, 10 percent owner, officer: See Remarks | C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139 |
Tracy Zimmermann | officer: Chief Development Officer | C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142 |
Cooper Ronald Harold Wilfred | director | C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140 |
Mark D. Angelino | officer: Chief Operating Officer | GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142 |
From GuruFocus
By sperokesalga sperokesalga • 03-23-2023
By sperokesalga sperokesalga • 03-21-2023
By sperokesalga sperokesalga • 05-10-2023
By Stock market mentor Stock market mentor • 01-03-2023
By GuruFocus Research • 12-06-2023
By sperokesalga sperokesalga • 05-31-2023
By GuruFocusNews GuruFocusNews • 07-02-2022
By Marketwired • 10-18-2023
By GuruFocusNews GuruFocusNews • 06-21-2022
By Value_Insider Value_Insider • 11-03-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.